The New Strategic CDMO: Bringing End-To-End Solutions For Better And Faster Drug Development

By William E. Weiser, Executive Director, Global Head Analytical Sciences, Patheon

By William E. Weiser, Executive Director, Global Head Analytical Sciences

While Big Pharma historically has kept development activities and CMC management in-house, unpredictable pipelines and increasing drug complexity have compelled the industry to look more seriously at outsourcing drug development and manufacturing to increase productivity and throughput. Bill Weiser, the executive director and global head of analytical sciences at Patheon, discusses how a new generation of CDMOs have positioned themselves to provide more strategic solutions that not only complement product development but also drive therapies to patients faster.